SIADH — Syndrome of Inappropriate Antidiuretic Hormone

Table of Contents

  1. Overview
  2. Physiology of ADH and Water Balance
  3. Epidemiology
  4. Causes of SIADH
  5. Diagnostic Criteria (Schwartz-Bartter Criteria)
  6. Clinical Presentation — Symptoms of Hyponatremia
  7. Diagnosis and Differential Diagnosis
  8. Treatment — Fluid Restriction and Beyond
  9. Pharmacological Treatments
  10. The Danger of Overcorrection — Osmotic Demyelination
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Overview

SIADH — the Syndrome of Inappropriate Antidiuretic Hormone Secretion — is the most common cause of euvolemic hyponatremia and the single most common cause of hyponatremia overall in hospitalized patients. It is not one disease but a clinical syndrome with dozens of causes, all sharing the same final common pathway: antidiuretic hormone (ADH, also called vasopressin or arginine vasopressin/AVP) is released when it should not be.

In a healthy person, ADH is secreted only when the blood is too concentrated (high osmolality) or blood volume/pressure is too low. In SIADH, neither trigger is present — yet ADH pours into the bloodstream due to pathological stimuli (brain disease, lung disease, cancer, medications, and more). The kidneys obediently hold onto water, diluting the blood. The result is dilutional hyponatremia: low serum sodium caused not by sodium loss, but by excess water retention, with blood volume that is normal or slightly expanded.

Hyponatremia (serum sodium below 135 mEq/L) is the most common electrolyte disorder in clinical medicine. It affects 15–30% of hospitalized patients and carries significant morbidity — including seizures, coma, brain herniation, and death in severe cases. SIADH accounts for approximately 35–40% of all hyponatremia cases. The diagnosis is one of exclusion: before calling it SIADH, thyroid and adrenal function must be confirmed normal, diuretic use must be absent, and volume status must be confirmed as euvolemic (not depleted, not overloaded).

Back to Table of Contents

Physiology of ADH and Water Balance

Understanding SIADH requires first understanding how ADH normally works — and why its inappropriate release is so harmful.

Where ADH Comes From

ADH (arginine vasopressin, AVP) is a 9-amino-acid peptide synthesized in two hypothalamic nuclei: the supraoptic nucleus and the paraventricular nucleus. It travels down axons to the posterior pituitary (neurohypophysis), where it is stored in granules and released into the bloodstream on demand.

Normal Triggers for ADH Release

  1. Increased plasma osmolality: Specialized osmoreceptors in the hypothalamus (near the supraoptic nucleus) are exquisitely sensitive — even a 1–2% rise above the normal threshold of approximately 285 mOsm/kg triggers ADH release. The osmoreceptors literally shrink when plasma is too concentrated, firing signals that release ADH.
  2. Decreased blood volume or pressure: Baroreceptors in the left atrium, carotid sinus, and aortic arch sense low stretch (= low volume or low pressure) and signal the hypothalamus to release ADH. Importantly, volume depletion can override osmolality — even if plasma is already dilute (low osmolality), significant volume loss will still trigger ADH. This is why severe vomiting or diarrhea causes water retention even when sodium is already low.
  3. Nausea: One of the most potent non-osmotic triggers for ADH. Even the sensation of nausea — mediated through chemoreceptor trigger zone pathways — rapidly elevates ADH levels. This is clinically important: postoperative nausea is a key reason surgical patients develop hyponatremia.
  4. Pain and stress: Both stimulate ADH release through hypothalamic stress pathways.

How ADH Works in the Kidney

ADH binds to V2 receptors on the principal cells of the renal collecting duct. This activates adenylyl cyclase, raises intracellular cAMP, and triggers insertion of aquaporin-2 (AQP2) water channels into the luminal membrane. These channels allow water to flow freely from the tubule into the concentrated medullary interstitium, producing concentrated urine and retaining water in the body. When plasma osmolality then falls back to normal, the osmoreceptors stop firing, ADH falls, AQP2 channels are withdrawn, and the kidney returns to excreting dilute urine — a perfectly self-correcting feedback loop.

What Goes Wrong in SIADH

In SIADH, ADH is secreted continuously despite normal or low plasma osmolality and normal or expanded blood volume. No legitimate trigger is present — yet the posterior pituitary keeps releasing ADH (or, in malignancy, the tumor itself secretes an ADH-like peptide). The kidneys cannot distinguish appropriate from inappropriate ADH. They keep reabsorbing water, the blood becomes progressively diluted, and serum sodium falls.

A secondary consequence develops over time: the expanded blood volume suppresses the renin-angiotensin-aldosterone system (RAAS). With aldosterone low, the kidney loses sodium in the urine — a process called renal escape or pressure natriuresis. This natriuresis explains why urine sodium is paradoxically high in SIADH (typically above 40 mEq/L) even as serum sodium falls. The body "gives away" sodium it cannot afford to lose, worsening the hyponatremia.

Back to Table of Contents

Epidemiology

Hyponatremia is the most common electrolyte disorder encountered in both inpatient and outpatient settings. Its prevalence in hospitalized patients ranges from 15% to 30% depending on the population studied and the sodium threshold used. Among all causes of hyponatremia, SIADH is the single most frequent — responsible for approximately 35–40% of cases.

In the ambulatory population, the incidence of clinically recognized SIADH is estimated at approximately 6 per million per year, but this figure dramatically underestimates the true burden because mild chronic SIADH is systematically underdiagnosed. In specialized hospital settings — oncology wards, neurosurgical ICUs, medical ICUs — the prevalence of SIADH can reach 20–30% of all admissions.

Age and Sex

SIADH becomes significantly more prevalent with advancing age. Adults over 65 are more vulnerable for several reasons: reduced baseline renal diluting capacity (fewer functional nephrons), higher rates of polypharmacy (especially SSRIs, diuretics, anticonvulsants), higher rates of underlying malignancy, and more frequent pulmonary and central nervous system comorbidities. Women of reproductive age face a specific danger with acute severe hyponatremia: progesterone inhibits the brain-cell adaptation mechanism that normally compensates for low sodium, making women at this life stage more susceptible to severe cerebral edema for any given drop in sodium level.

The Hidden Burden of Chronic Mild Hyponatremia

Even sodium levels in the 125–134 mEq/L range — often dismissed as "mild" — carry real consequences. Studies have shown that chronic mild hyponatremia triples the risk of falls, is associated with gait instability that rivals many neurological disorders, and correlates with increased hip fracture risk, partly because sodium is stored in bone and chronic depletion demineralizes the matrix. Cognitive impairment in the chronic mildly hyponatremic patient is often subtle but measurable on neuropsychological testing. These consequences make early identification and treatment of SIADH — even in its milder forms — a meaningful clinical priority.

Back to Table of Contents

Causes of SIADH

The causes of SIADH are conveniently grouped into five categories: Central Nervous System disorders, Pulmonary disorders, Malignancy, Medications, and Other. In clinical practice, a thorough medication review and chest imaging should always be performed, as drugs and occult malignancy are among the most common and correctable causes.

CNS Causes

Any injury or inflammation to the brain can stimulate inappropriate ADH release by disrupting the hypothalamic-pituitary axis or irritating hypothalamic osmoreceptor circuitry:

Pulmonary Causes

Lung disease causes SIADH through two mechanisms: ectopic ADH production from pulmonary tissue, and stimulation of intrathoracic baroreceptors by reduced venous return or hypoxia:

Malignancy (Ectopic ADH Production)

Some tumors synthesize and secrete ADH or ADH-like peptides independently of hypothalamic control — classic ectopic hormone production:

Medications

Drug-induced SIADH is extremely common — particularly in older adults on multiple medications. Always perform a complete medication review. The most important offenders:

Other Causes

Back to Table of Contents

Diagnostic Criteria (Schwartz-Bartter Criteria)

SIADH was first defined in 1957 by Schwartz and Bartter based on observations of two patients with lung cancer and hyponatremia. Their original criteria — refined over subsequent decades — remain the diagnostic standard. All six criteria must be met simultaneously to diagnose SIADH:

  1. Hyponatremia with hypoosmolality: Serum sodium below 135 mEq/L with measured plasma osmolality below 275 mOsm/kg. This confirms true hypotonic hyponatremia — eliminating pseudo-hyponatremia (elevated proteins or lipids that artifactually lower sodium on some analyzers but leave osmolality normal) and the translocational hyponatremia of hyperglycemia (water shifts from cells when glucose is high, lowering Na even though total body sodium is unchanged).
  2. Urine osmolality above 100 mOsm/kg: In any normal person with plasma osmolality below 275 mOsm/kg, ADH should be fully suppressed and the kidney should produce maximally dilute urine (osmolality near 50–100 mOsm/kg). Urine osmolality above 100 mOsm/kg in the setting of plasma hypo-osmolality means ADH is active when it should not be — the defining biochemical lesion of SIADH. In practice, SIADH typically produces urine osmolality of 300–600 mOsm/kg.
  3. Urine sodium above 40 mEq/L: Volume expansion from water retention suppresses aldosterone via the RAAS, leading to urinary sodium wasting (natriuresis). In hypovolemic hyponatremia — where the kidney is trying to conserve sodium — urine sodium would be below 20 mEq/L. High urine sodium in the setting of hyponatremia distinguishes SIADH (and other euvolemic states) from dehydration, vomiting, or diarrhea.
  4. Clinical euvolemia: The patient must have no signs of volume depletion (no dry mucous membranes, no skin tenting, no orthostatic hypotension, no tachycardia) and no signs of volume overload (no peripheral edema, no ascites, no elevated jugular venous pressure). Heart failure, cirrhosis, and nephrotic syndrome all cause hyponatremia with high urine sodium in some settings but are accompanied by hypervolemia and are therefore NOT SIADH.
  5. Normal adrenal and thyroid function: Both hypothyroidism and glucocorticoid deficiency cause a clinical picture indistinguishable from SIADH biochemically. Both are treatable with hormone replacement — a completely different intervention than fluid restriction or vaptans. TSH and morning cortisol (or ACTH stimulation testing) are mandatory before diagnosing SIADH. Missing adrenal insufficiency is particularly dangerous, as the associated hemodynamic instability can be fatal.
  6. No recent diuretic use: Thiazide and loop diuretics raise urine sodium regardless of volume status (by their mechanism of blocking tubular sodium reabsorption), and can cause euvolemic-appearing hyponatremia. If a patient is on diuretics, the diagnosis of SIADH cannot be reliably made until diuretics are held and the sodium pattern reassessed.

Back to Table of Contents

Clinical Presentation — Symptoms of Hyponatremia

The symptoms of SIADH are entirely the symptoms of hyponatremia. Their severity depends on two variables: the absolute sodium level and, critically, the rate of fall. A sodium of 120 mEq/L that developed over months may produce only subtle symptoms, while the same level reached over 24 hours can cause fatal cerebral edema. This is because the brain has a remarkable capacity to adapt to gradual changes in osmolality by extruding organic osmolytes (inositol, glutamate, taurine, creatine) — a process that takes 24–48 hours to complete.

Mild to Moderate (Sodium 125–134 mEq/L)

Often entirely asymptomatic, or producing only subtle symptoms that are easily attributed to other causes: fatigue, mild nausea, anorexia, and mild cognitive dulling. The danger here is that "asymptomatic" does not mean "harmless." Large epidemiological studies have demonstrated that chronic mild hyponatremia:

Moderate to Severe (Sodium 115–124 mEq/L)

Headache, confusion, lethargy, personality changes, and muscle cramps become prominent. Concentration and short-term memory are impaired. The patient may appear intoxicated.

Severe (Sodium Below 115 mEq/L)

This is a neurological emergency. Cerebral edema leads to:

Women of reproductive age face a specific biological vulnerability. Progesterone inhibits the Na⁺/K⁺-ATPase pump that brain cells use to extrude sodium and water as an adaptive response to hyponatremia. This means that for the same sodium level and the same rate of fall, premenopausal women experience greater degrees of cerebral edema than men or postmenopausal women. Several high-profile cases of young healthy women dying from hyponatremia (marathon runners, MDMA users, postoperative patients given excess hypotonic fluids) reflect this biological difference. Awareness of this vulnerability is critical when managing acute hyponatremia in women of reproductive age.

Back to Table of Contents

Diagnosis and Differential Diagnosis

Initial Laboratory Workup

The following tests should be obtained simultaneously in any patient with hyponatremia:

Imaging and Other Tests

Differential Diagnosis of Euvolemic Hyponatremia

Back to Table of Contents

Treatment — Fluid Restriction and Beyond

Treatment strategy depends on whether hyponatremia is acute or chronic, severe or mild, and symptomatic or not. The correction rate is as important as the correction target — too slow risks ongoing neurological injury in acute severe cases; too fast risks osmotic demyelination syndrome in chronic cases.

1. Treat the Underlying Cause

This is always the first priority and may be sufficient alone. Stopping an offending medication, treating pneumonia with antibiotics, resecting a small cell lung cancer, replacing thyroid hormone in hypothyroidism, or giving glucocorticoids in adrenal insufficiency can normalize sodium without further specific therapy.

2. Fluid Restriction (First-Line for Chronic Mild-to-Moderate SIADH)

Restricting total fluid intake to 500–800 mL per day creates a negative water balance: the kidneys continue excreting concentrated urine while less water enters the system, gradually raising serum sodium. The target correction rate is 6–8 mEq/L per 24 hours for chronic hyponatremia. Fluid restriction is simple, inexpensive, and avoids the risks of hypertonic saline or vaptan therapy.

Practical challenges: strict compliance is difficult (thirst is intense when sodium is low), all fluids count including coffee and soup, and the approach is slow. The response depends on the ratio of urine osmolality to plasma osmolality (Uosm/Posm): if this ratio exceeds 1, more water must be restricted to achieve negative water balance, and Uosm/Posm greater than 2 suggests fluid restriction alone is often inadequate — adjunctive therapy is needed.

Patient education is essential: explain that every sip of fluid — even water, tea, juice, broth, or liquid medications — counts toward the daily limit.

3. High Solute Intake (Oral Salt Tablets and Urea)

Increasing dietary solute raises the osmotic "carrying capacity" of urine. More solute means the kidney must excrete more water with each liter of urine to maintain isotonicity in the medullary interstitium:

4. Hypertonic Saline (3% NaCl) — Acute Severe Symptomatic Hyponatremia

When a patient has seizures, coma, respiratory failure, or signs of acute brain herniation due to hyponatremia, rapid correction with 3% hypertonic saline is necessary and lifesaving:

Correction Rate Rules

Back to Table of Contents

Pharmacological Treatments

Several pharmacological options exist for SIADH that does not respond adequately to fluid restriction and solute loading, or when the underlying cause cannot be removed:

Vaptans — V2 Receptor Antagonists (Aquaretics)

Vaptans are the most mechanistically targeted treatment for SIADH. They block the V2 receptor on renal collecting duct cells — the same receptor that ADH activates. By blocking this receptor, aquaporin-2 channels are not inserted, and water is excreted without sodium loss. This is called aquaresis (water-only diuresis), distinguishing it from the sodium-and-water diuresis of conventional diuretics.

Demeclocycline

A tetracycline antibiotic that causes nephrogenic diabetes insipidus as a side effect — meaning it blocks the action of ADH in the collecting duct. Used before vaptans were available and still occasionally used in settings where vaptans are not accessible. Significant drawbacks: slow onset of action (3–6 days), dose-dependent nephrotoxicity (especially in patients with cirrhosis or low GFR), and photosensitivity. Largely replaced by vaptans in current practice.

Urea (Oral)

As noted in the treatment section, oral urea at doses of 30–60 grams per day in divided doses is a highly effective and underutilized treatment. It is particularly attractive because it is safe in hepatic and renal disease (unlike tolvaptan), carries no risk of osmotic demyelination overshoot (urea equilibrates freely across brain cell membranes), and is inexpensive. Its main limitation is taste — it requires creative mixing to achieve patient compliance. In Europe, where urea is more widely used, it is the preferred second-line agent after fluid restriction.

Loop Diuretics Plus Oral Salt

Furosemide 20–40 mg daily combined with oral sodium chloride tablets (3 grams three times daily) is a time-tested combination. The loop diuretic forces isotonic urine output (disrupting the medullary concentrating gradient), while oral salt replaces urinary sodium losses and raises the serum sodium directly. This approach is particularly useful in patients with reset osmostat or in the elderly who tolerate fluid restriction poorly.

Back to Table of Contents

The Danger of Overcorrection — Osmotic Demyelination

Osmotic demyelination syndrome (ODS) — formerly called central pontine myelinolysis (CPM) — is among the most feared iatrogenic neurological disasters in medicine. It is caused entirely by the treatment of hyponatremia: specifically, by correcting chronic hyponatremia too rapidly.

Why Rapid Correction Destroys Myelin

When the brain has been chronically hyponatremic for more than 48 hours, its cells adapt by extruding organic osmolytes — inositol, glutamate, glutamine, taurine, and creatine — to reduce intracellular osmolality and prevent cell swelling. This adaptation works over days. If sodium is then corrected rapidly, the plasma becomes acutely hyperosmolar relative to the brain. Water rushes out of brain cells down the new osmotic gradient — but the osmolytes that were pumped out take several days to return. The result is acute cell dehydration and shrinkage in the pontine myelin-producing oligodendrocytes, which are particularly vulnerable. Their myelin sheaths rupture, producing a characteristic pattern of demyelination in the central pons and sometimes extending to extrapontine sites (basal ganglia, thalamus, cerebellum, cortex).

Clinical Presentation

The tragedy of ODS is its delayed onset. After initially improving with sodium correction, the patient deteriorates 2–7 days later as the demyelination becomes clinically manifest:

Many patients with severe ODS do not recover. Even survivors often have permanent neurological disability. MRI shows characteristic T2/FLAIR hyperintensity in the central pons — the "trident" or "bat wing" pattern — though MRI changes may lag clinical symptoms by several days.

Risk Factors

Not all patients are equally vulnerable. High-risk patients include:

Prevention Is Everything

ODS is entirely preventable if sodium correction rates are respected:

Emergency Management of Overcorrection

If sodium has risen more than 10–12 mEq/L in 24 hours, or the patient approaches the 48-hour limit prematurely, act immediately:

  1. Stop all hypertonic saline, vaptans, and solute loading
  2. Administer desmopressin (DDAVP) 2 mcg IV every 6–8 hours — this restores ADH effect and causes the kidney to retain water again, lowering sodium
  3. Simultaneously infuse D5W (5% dextrose in water) at a rate calculated to lower sodium back to within the safe correction range (no more than 10 mEq/L above starting value over 24 hours)
  4. Check sodium every 2 hours until stable within the safe range

This deliberate relowering strategy has been validated in case series and is accepted in major clinical guidelines. It is safe and effective when implemented promptly. The window for intervention is the first 12–24 hours after overcorrection — before the osmotic injury becomes irreversible.

Back to Table of Contents

Key Research Papers

  1. Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med. 1957;23(4):529–542. PMID: 13469824 — The original 1957 description of SIADH that established its defining criteria.
  2. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356(20):2064–2072. PMID: 17538088 — Authoritative clinical review covering diagnosis, etiology, and management.
  3. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1–S42. PMID: 24074529 — Comprehensive American expert panel guidelines on hyponatremia management.
  4. Hoorn EJ, Zietse R. Diagnosis and treatment of hyponatremia: compilation of the guidelines. J Am Soc Nephrol. 2017;28(5):1340–1349. PMID: 27797881 — Synthesis comparing American and European hyponatremia guidelines.
  5. Berl T. Vasopressin antagonists. N Engl J Med. 2015;372(23):2207–2216. PMID: 26244307 — Comprehensive review of vaptan mechanism, efficacy, and clinical use in SIADH.
  6. Soupart A, Decaux G. Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications. Clin Nephrol. 1996;46(3):149–169. PMID: 8788169 — Foundational review on osmotic demyelination risk and safe correction rates.
  7. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119(7 Suppl 1):S30–S35. PMID: 16428870 — Epidemiological data establishing hyponatremia's prevalence and SIADH's contribution.
  8. Ayus JC, Varon J, Arieff AI. Hyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runners. Ann Intern Med. 2000;132(9):711–714. PMID: 10792366 — Case series documenting exertional hyponatremia and sex-specific vulnerability in distance runners.
  9. Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol. 2009;29(3):282–299. PMID: 19615551 — Detailed treatment algorithm covering hypertonic saline, vaptans, and overcorrection management.
  10. Furst H, Hallows KR, Post J, et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci. 2000;319(4):240–244. PMID: 10784373 — Explains and validates the Uosm/Posm ratio for predicting fluid restriction response.
  11. Decaux G, Musch W. Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone. Clin J Am Soc Nephrol. 2008;3(4):1175–1184. PMID: 18045855 — Laboratory criteria and biomarkers (including uric acid and FEUrea) for SIADH diagnosis.
  12. Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170(3):G1–G47. PMID: 24569125 — European Society of Endocrinology joint clinical guidelines, including strong support for oral urea.

PubMed Topic Searches

  1. SIADH syndrome inappropriate antidiuretic hormone — PubMed
  2. Hyponatremia treatment hypertonic saline — PubMed
  3. Osmotic demyelination syndrome central pontine myelinolysis — PubMed
  4. Tolvaptan hyponatremia SIADH — PubMed
  5. SSRI-induced hyponatremia elderly — PubMed
  6. Small cell lung cancer SIADH paraneoplastic — PubMed

Back to Table of Contents

Connections

Back to Table of Contents